EC Microbiology

Review Article Volume 17 Issue 2 - 2021

Immune Thrombocytopenic Purpura in Review

Mohammed Saleh Ali Hussein1*, Alaa A Alghamdi2, Nalah Yahya Al Mani3, Nashwa Mohammed Alzahrani4, Habeeba Yahya Al-Marshaq5, Fatima Moajel Alshammari6, Hussain Ali Alhazmi7, Amal Saleh Alrashed8, Asiah Ahmad Al Bin Abdullah9, Ahmad Saud Mohammed Alaskar10, Hussain Abdulmohsin Alsadiq11, and Eman Meshal Alotabi12.

1* Consultant Gastroenterology, Professor of Internal Medicine, Dr Samir Abbas Hospital, Jeddah, Saudi Arabia
2* Alfaisal University, Saudi Arabia
3* Najran University, Saudi Arabia
4* Teaching Assistant Northern Border University, Umm Alqura University Graduate, Saudi Arabia
5* University of Science and Technology, Saudi Arabia
6* Hail University, Saudi Arabia
7* General Practitioner, Damad General Hospital, Saudi Arabia
8* Primary Health Care, Alahssa, Saudi Arabia
9* Khamis Mushait Maternity Children Hospital, Saudi Arabia
10* Imam Mohammed Ibn Saud Islamic University, Riyadh, Saudi Arabia
11* Dammam Medical Complex, Saudi Arabia
12* Administration of Health Programs and Chronic Diseases in Public Health in Makkah, Saudi Arabia

*Corresponding Author: Mohammed Saleh Ali Hussein, Consultant Gastroenterology, Professor of Internal Medicine, Dr Samir Abbas Hospital, Jeddah, Saudi Arabia.
Received: December 14, 2020; Published: January 18, 2021




Background: Immune thrombocytopenic purpura (ITP) characterized by high risk of bleeding, this bleeding is due to 2 main factors the first is the damage of the platelets which is mediated by antibodies and also disordered platelet synthesis, all the previous char- acteristics identify Immune thrombocytopenic purpura (ITP) as autoimmune disease.

Aim: In this review, we will look into the prevalence, pathophysiology, diagnosis and management of immune thrombocytopenic purpura.

Conclusion: ITP is a serious disease that cause sever bleeding that can be life threatening in some cases, the causes of this disease are idiopathic mostly but it is classifies as autoimmune disease, the diagnosis of ITP is mainly by excluding other causes that can give the same symptoms. Treatment is classified into three steps if one fails, we move to the next one starting from corticosteroids, then splenectomy and finally the new group of medications whose mechanism, and data are not sufficient so more studies should be conducted.

 Keywords: Immune Thrombocytopenic Purpura; Management of Immune Thrombocytopenic Purpura; Immune Thrombocytopenic Purpura Diagnosis; ITP Prevalence

  1. Cines DB and Blanchette VS. “Immune thrombocytopenic purpura”. The New England Journal of Medicine 346.13 (2002): 995-1008.
  2. Zufferey A., et al. “Pathogenesis and therapeutic mechanisms in immune thrombocytopenia (ITP)”. Journal of Clinical Medicine 6 (2017): 16.
  3. Cines DB., et al. “The ITP syndrome: pathogenic and clinical diversity”. Blood 113 (2009): 6511-6521.
  4. Cines DB and Blanchette VS. “Immune thrombocytopenic purpura”. The New England Journal of Medicine 346 (2002): 9951008.
  5. George JN., et al. “Idiopathic thrombocytopenic purpura: a practice guideline developed by explicit methods for the American Society of Hematology”. Blood 88.1 (1996): 3-40.
  6. Frederiksen H and Schmidt K. “The incidence of idiopathic thrombocytopenic purpura in adults increases with age”. Blood 94.3 (1999): 909-913.
  7. Neunert C., et al. “The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia”. Blood 117 (2011): 4190-4207.
  8. Cines DB and Blanchette VS. “Immune thrombocytopenic purpura”. The New England Journal of Medicine 346 (2002): 995-1008.
  9. Lambert MP and Gernsheimer TB. “Clinical updates in adult immune thrombocytopenia”. Blood 129 (2017): 2829-2835.
  10. Fogarty PF and Segal JB. “The epidemiology of immune thrombocytopenic purpura”. Current Opinion in Hematology 14 (2007): 515-519.
  11. George JN., et al. “Idiopathic thrombocytopenic purpura: A practice guideline developed by explicit methods for the American Society of Hematology”. Blood 88 (1996): 3-40.
  12. British Committee for Standards in Haematology. “Guidelines for the investigation and management of idiopathic thrombocytopenic purpura in adults, children and in pregnancy”. British Journal of Haematology 120 (2003): 574-596.
  13. Cines DB and Blanchette VS. “Immune thrombocytopenic purpura”. The New England Journal of Medicine 346 (2002): 995-1008.
  14. Cines DB., et al. “The ITP syndrome: Pathogenic and clinical diversity”. Blood 113 (2009): 6511-6521.
  15. Rodeghiero F., et al. “Standardization of terminology, definitions, and outcome criteria in immune thrombocytopenic purpura (ITP) in adults and children. Report from an international working group”. Blood 113 (2009): 2386-2393.
  16. Provan D., et al. “International consensus report on the investigation and management of primary immune thrombocytopenia”. Blood.
  17. Cohn J. “Thrombocytopenia in childhood: An evaluation of 433 patients”. Scandinavian Journal of Haematology 16 (1976): 226-240.
  18. Watts RG. “Idiopathic thrombocytopenic purpura: A 10-year natural history study at the Childrens Hospital of Alabama”. Clinical Pediatrics 43 (2004): 691-702.
  19. Lilleyman JS. “Intracranial hemorrhage in idiopathic thrombocytopenic purpura”. Archives of Disease in Childhood 71 (1994): 251-253.
  20. Zeller B., et al. “Immune thrombocytopenic purpura in childhood in Norway: A prospective, population-based registration”. Pediatric Hematology and Oncology 17 (2000): 551-558.
  21. Zeller B., et al. “Childhood idiopathic thrombocytopenic purpura in the Nordic countries: Epidemiology and predictors of chronic disease”. Acta Paediatrics 94 (2005): 178-184.
  22. Bolton-Maggs PHB and Moon I. “Assessment of UK practice for management of acute childhood idiopathic thrombocytopenic purpura against published guidelines”. Lancet 350 (1997): 620-623.
  23. Reid MM. “Chronic idiopathic thrombocytopenic purpura: Incidence, treatment, and outcome”. Archives of Disease in Childhood 72 (1995): 125-128.
  24. Frederiksen H and Schmidt K. “The incidence of ITP in adults increases with age”. Blood 94 (1999): 909-913.
  25. Neylon AJ., et al. “Clinically significant newly presenting autoimmune thrombocytopenic purpura in adults: A prospective study of a population-based cohort of 245 patients”. British Journal of Haematology 122 (2003): 966-974.
  26. Abrahamson PE., et al. “The incidence of idiopathic thrombocytopenic purpura among adults: A population-based study and literature review”. European Journal of Haematology 83 (2009): 83-89.
  27. Stasi R and Newland AC. “ITP: a historical perspective”. British Journal of Haematology 153.4 (2011): 437-450.
  28. Nazy I., et al. “Autoantibodies to thrombopoietin and the thrombopoietin receptor in patients with immune thrombocytopenia”. Blood 128.22 (2016): 2548.
  29. Cines DB and Blanchette VS. “Immune thrombocytopenic purpura”. New England Journal of Medicine 346.13 (2002): 995-1008.
  30. Imbach P and Crowther M. “Thrombopoietin-receptor agonists for primary immune thrombocytopenia”. New England Journal of Medicine 365.8 (2011): 734-741.
  31. Frydman GH., et al. “Helicobacter pylori eradication in patients with immune thrombocytopenic purpura: a review and the role of biogeography”. Helicobacter 20.4 (2015): 239-251.
  32. Bohn JP and Steurer M. “Current and evolving treatment strategies in adult immune thrombocytopenia”. Memo 11.3 (2018): 241-246.
  33. Matzdorff A., et al. “Immune thrombocytopenia - current diagnostics and therapy: recommendations of a joint working group of DGHO, OGHO, SGH, GPOH, and DGTI”. Oncology Research and Treatment 41.5 (2018): 1-30.
  34. Kiefel V., et al. “Monoclonal antibody-specific immobilization of platelet antigens (MAIPA): a new tool for the identification of platelet-reactive antibodies”. Blood 70 (1987): 1722-1726.
  35. Brighton TA., et al. “Prospective evaluation of the clinical usefulness of an antigen-specific assay (MAIPA) in idiopathic thrombocytopenic purpura and other immune thrombocytopenias”. Blood 88 (1996): 194-201.
  36. Warner MN., et al. “A prospective study of protein-specific assays used to investigate idiopathic thrombocytopenic purpura”. British Journal of Haematology 104 (1999): 442-447.
  37. Raife TJ., et al. “Platelet antibody testing in idiopathic thrombocytopenic purpura”. Blood 89 (1996): 1112-1114.
  38. Berchtold P., et al. “International study to compare antigen-specific methods used for the measurement of antiplatelet autoantibodies”. British Journal of Haematology 96 (1997): 477-483.
  39. Taub JW., et al. “Characterization of autoantibodies against the platelet glycoprotein antigens IIb/IIIa in childhood idiopathic thrombocytopenic purpura”. American Journal of Hematology 48 (1995): 104-107.
  40. Zufferey A., et al. “Pathogenesis and therapeutic mechanisms in immune thrombocytopenia (ITP)”. Journal of Clinical Medicine 6 (2017): 16.
  41. Cheng Y., et al. “Initial treatment of immune thrombocytopenic purpura with high-dose dexamethasone”. The New England Journal of Medicine 349 (2003): 831-836.
  42. Matschke J., et al. “A randomized trial of daily prednisone versus pulsed dexamethasone in treatment-naive adult patients with immune thrombocytopenia: EIS 2002 study”. Acta Haematologica 136 (2016): 101-107.
  43. Depre F., et al. “Efficacy and tolerability of old and new drugs used in the treatment of immune thrombocytopenia: results from a long-term observation in clinical practice”. PLoS One 13 (2018): 0198184.
  44. Depre F., et al. “Efficacy and tolerability of old and new drugs used in the treatment of immune thrombocytopenia: results from a long-term observation in clinical practice”. PLoS One 13 (2018): 0198184.
  45. Neunert C., et al. “The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia”. Blood 117 (2011): 4190-4207.
  46. Nomura S. “Advances in diagnosis and treatments for immune thrombocytopenia”. Clinical Medicine Insights: Blood Disorders 9 (2016): 15-22.
  47. Bussel JB and Pham LC. “Intravenous treatment with gammaglobulin in adults with immune thrombocytopenic purpura: review of the literature”. Vox Sanguinis 52 (1987): 206-211.
  48. Mayer B., et al. “New aspects on the efficacy of high-dose intravenous immunoglobulins in patients with autoimmune thrombocytopenia”. Vox Sanguinis 112 (2017): 64-69.
  49. Cines DB and Blanchette VS. “Immune thrombocytopenic purpura”. The New England Journal of Medicine 346 (2002): 995-1008.
  50. Hammond WA., et al. “Splenectomy or rituximab in steroid-refractory immune thrombocytopenia (ITP): the Mayo Clinic experience”. Blood 128 (2016): 3735-3735.
  51. Rodeghiero F., et al. “Standardization of bleeding assessment in immune thrombocytopenia: report from the International Working Group”. Blood 121 (2013): 2596-2606.
  52. Vianelli N., et al. “Efficacy and safety of splenectomy in immune thrombocytopenic purpura: long-term results of 402 cases”. Haematologica 90 (2005): 72-77.
  53. Guan Y., et al. “Long-term results of splenectomy in adult chronic immune thrombocytopenia”. European Journal of Haematology 98 (2017): 235-241.
  54. Cordera F., et al. “Open versus laparoscopic splenectomy for idiopathic thrombocytopenic purpura: clinical and economic analysis”. Surgery 134 (2003): 45-52.
  55. Moulis G., et al. “Rituximab versus splenectomy in persistent or chronic adult primary immune thrombocytopenia: an adjusted comparison of mortality and morbidity”. American Journal of Hematology 89 (2014): 41-46.
  56. Al Askar AS., et al. “Splenectomy vs. rituximab as a second-line therapy in immune thrombocytopenic purpura: a single center experience”. International Journal of Hematology 107 (2018): 69-74.
  57. Chang H., et al. “Immune thrombocytopenia: effectiveness of frontline steroids and comparison of azathioprine, splenectomy, and rituximab as second-line treatment”. European Journal of Haematology 101 (2018): 549-555.
  58. Quiquandon I., et al. “Re-evaluation of the role of azathioprine in the treatment of adult chronic idiopathic thrombocytopenic purpura: a report on 53 cases”. British Journal of Haematology 74 (1990): 223-228.
  59. Bourgeois E., et al. “Long-term followup of chronic autoimmune thrombocytopenic purpura refractory to splenectomy: a prospective analysis”. British Journal of Haematology 120 (2003): 1079-1088.

Mohammed Saleh Ali Hussein., et al. “Immune Thrombocytopenic Purpura in Review”. EC Microbiology 17.2(2021): 100-108.

ECronicon Journal

Our Services

Quick Links

Information

Creative Commons LicenseOpen Access by ECronicon is licensed under a Creative Commons Attribution 4.0 International License
Based on a work at www.ecronicon.net